Immunocore Holdings Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Bahija Jallal

Chief Executive Officer (CEO)

US$11.7m

Compensación total

Porcentaje del salario del CEO	6.3%
Permanencia del CEO	5.8yrs
Participación del CEO	n/a
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	5.2yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Bahija Jallal en comparación con los beneficios de Immunocore Holdings?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$47m
Jun 30 2024	n/a	n/a	-US$55m
Mar 31 2024	n/a	n/a	-US$60m
Dec 31 2023	US$12m	US$735k	-US$55m
Sep 30 2023	n/a	n/a	-US$69m
Jun 30 2023	n/a	n/a	-US$61m
Mar 31 2023	n/a	n/a	-US$52m
Dec 31 2022	US$1m	US$700k	-US$53m
Sep 30 2022	n/a	n/a	-US$62m
Jun 30 2022	n/a	n/a	-US$112m
Mar 31 2022	n/a	n/a	-US$156m
Dec 31 2021	US$35m	US$700k	-US$180m
Sep 30 2021	n/a	n/a	-US$150m
Jun 30 2021	n/a	n/a	-US$139m
Mar 31 2021	n/a	n/a	-US$116m
Dec 31 2020	US$1m	n/a	-US$101m

Compensación vs. Mercado: La compensación total de Bahija($USD11.68M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.64M).

Compensación vs. Ingresos: La compensación de Bahija ha aumentado mientras la empresa no es rentable.

CEO

Bahija Jallal (63 yo)

5.8yrs

Permanencia

US$11,678,834

Compensación

Dr. Bahija Jallal, Ph.D. serves as Director of Outpace Bio, Inc. from March 2023. She serves as Chief Executive Officer and Director of Immunocore Holdings plc (formerly known as Immunocore Holdings Limite...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Bahija Jallal	CEO & Executive Director	5.8yrs	US$11.68m	sin datos
Brian Di Donato	Executive VP	4.6yrs	US$3.35m	0.038% € 601.8k
Tina Leger	Chief Human Resources Officer	2.8yrs	US$1.04m	sin datos
David Berman	Executive Vice President of Research & Development	5.8yrs	US$4.40m	0% € 0
John Trainer	SVP & Chief Operating Officer	less than a year	sin datos	sin datos
John Goll	SVP, Finance & Chief Accounting Officer	less than a year	sin datos	sin datos
Annelise Vuidepot	Senior VP	no data	sin datos	sin datos
Sean Buckley	VP & Chief Information Officer	less than a year	sin datos	sin datos
Clayton Robertson	Head of Investor Relations	no data	sin datos	sin datos
Lily Hepworth	Senior VP	3.8yrs	sin datos	sin datos
Elizabeth Jobes	Chief Compliance Officer	less than a year	sin datos	sin datos
Sébastien Desprez	Vice President of Communications	2.8yrs	sin datos	sin datos

2.8yrs

Permanencia media

54.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 6YG se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Bahija Jallal	CEO & Executive Director	5.8yrs	US$11.68m	sin datos
John Bell	Independent Non-Executive Chairman	9.7yrs	US$416.99k	0.027% € 421.1k
Kristine Peterson	Independent Non-Executive Director	7yrs	US$389.49k	0% € 0
Robert Perez	Independent Non-Executive Director	5.2yrs	sin datos	sin datos
Roy Steven Herbst	Independent Non-Executive Director	3.8yrs	US$386.99k	0% € 0
Peter Ratcliffe	Independent Non-Executive Director	4yrs	US$384.49k	0.00067% € 10.5k
Ranjeev Krishana	Director	less than a year	sin datos	sin datos
Travis Coy	Independent Non-Executive Director	5.2yrs	sin datos	sin datos
Siddharth Kaul	Independent Non-Executive Director	2.4yrs	US$386.99k	0% € 0

5.2yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de 6YG se considera experimentada (5.2 años de antigüedad promedio).

Immunocore Holdings Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Immunocore Holdings plc Announces Brian Di Donato Plans to Leave At the End of the Year as Chief Financial Officer

Immunocore Holdings plc Appoints Ranjeev Krishana to Serve as A Class I Director

Insufficient new directors

Immunocore Holdings plc, Annual General Meeting, May 23, 2024

High number of new directors

High number of new directors

Recent updates

Third quarter 2024 earnings released: EPS: US$0.17 (vs US$0.018 in 3Q 2023)

New major risk - Revenue and earnings growth

Immunocore Presents Phase 1 Data of Brenetafusp, an Immtac Bispecific Targeting Prame, in Patients with Ovarian Cancer

Immunocore Holdings plc Announces Brian Di Donato Plans to Leave At the End of the Year as Chief Financial Officer

Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.35 loss in 2Q 2023)

Immunocore Holdings plc to Report Q2, 2024 Results on Aug 08, 2024

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Immunocore Holdings plc Announces Randomization of First Patient in the Global, Registrational Phase 3 Clinical Trial Testing Brenetafusp for the Treatment of First-Line Advanced or Metastatic Cutaneous Melanoma

Immunocore Holdings plc Presents KIMMTRAK Clinical Data Demonstrating That Patients with Stable Disease and Confirms Tumor Reduction Have Similar Clinical Outcomes to Patients with Partial Response

Immunocore Holdings plc Appoints Ranjeev Krishana to Serve as A Class I Director

Immunocore Holdings plc Converts Phase 2/3 TEBE-AM Clinical Trial into Registrational Phase 3 Trial Evaluating KIMMTRAK for Previously Treated Advanced Cutaneous Melanoma

Now 22% undervalued after recent price drop

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.49 loss per share (vs US$0.43 loss in 1Q 2023)

Insufficient new directors

Immunocore Holdings plc, Annual General Meeting, May 23, 2024

Full year 2023 earnings released: US$1.13 loss per share (vs US$1.09 loss in FY 2022)

Immunocore Holdings plc to Report Q4, 2023 Results on Feb 28, 2024

Immunocore Holdings plc Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2023

Immunocore Holdings plc Announces the Addition of Two New Pre-Clinical Candidates for Autoimmune Diseases to Its Pipeline

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: UK£0.04 (vs UK£0.13 in 3Q 2022)

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: UK£0.29 loss per share (vs UK£0.14 loss in 2Q 2022)

Immunocore Holdings plc to Report Q2, 2023 Results on Aug 10, 2023

First quarter 2023 earnings released: UK£0.35 loss per share (vs UK£0.37 loss in 1Q 2022)

Forecast breakeven date moved forward to 2024

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: UK£0.90 loss per share (vs UK£3.10 loss in FY 2021)

Immunocore Holdings plc Provides Revenue Guidance for the Fourth Quarter and Twelve Months Ended December 31, 2022

Immunocore Holdings plc Announces the Addition of Three New ImmTAC Product Candidates

Forecast to breakeven in 2025

Immunocore Holdings plc Presents Ovarian Cancer Expansion Data for ImmTAC® candidate IMC-C103C targeting MAGE-A4

An unknown buyer acquired a 5% stake in Immunocore Holdings plc (NasdaqGS:IMCR) from Malin Corporation plc (ISE:MLC) for approximately €150 million.

Third quarter 2022 earnings released: EPS: UK£0.13 (vs UK£0.69 loss in 3Q 2021)

High number of new directors

Second quarter 2022 earnings released

Immunocore Holdings plc to Report Q2, 2022 Results on Aug 10, 2022

High number of new directors

Immunocore Holdings plc announced that it has received $139.999988 million in funding from RTW Investments, LP, Rock Springs Capital Management LP, General Atlantic Service Company, L.P., Baker Bros. Advisors LP and another investor

Immunocore Holdings plc announced that it expects to receive $139.999988 million in funding from RTW Investments, LP, Rock Springs Capital Management LP, General Atlantic Service Company, L.P.

Immunocore Announces Dosing of First Patient with ImmTAV(R) Bispecific for HIV

High number of new directors

Immunocore Announces the Presentation of Initial Data from the Phase 1 Immtav® Trial for Chronic Hepatitis B At the EASL International Liver Congress™

Immunocore Holdings plc Appoints Siddharth (Sid) Kaul as A Non-Executive Member of Its Board of Directors

Immunocore Holdings plc Announces UK Medicines and Healthcare Products Regulatory Agency, Australian Therapeutic Goods Administration and Health Canada Approves Kimmtrak® (Tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma

Immunocore Holdings plc Presents New Data on KIMMTRAK (tebentafusp-tebn) in metastatic Cutaneous Melanoma (mCM) and metastatic Uveal Melanoma (mUM) at the 2022 American Society of Clinical Oncology Annual Meeting

Immunocore Announces Upcoming Presentations At the 2022 American Society of Clinical Oncology Annual Meeting

First quarter 2022 earnings released: UK£0.37 loss per share (vs UK£0.76 loss in 1Q 2021)

Immunocore Holdings plc, Annual General Meeting, May 12, 2022

European Commission Approves Immunocore Holdings plc's KIMMTRAK (Tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Immunocore Holdings plc Receives Positive CHMP Opinion for KIMMTRAK (Tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma

Immunocore Holdings plc Announces Approval from the United States Food and Drug Administration of KIMMTRAK for the Treatment of Unresectable or Metastatic Uveal Melanoma

Third quarter 2021 earnings released: UK£0.69 loss per share (vs UK£0.064 loss in 3Q 2020)

Immunocore Announces Publication of Phase 3 Data Comparing tebentafusp with Investigator’s Choice in the New England Journal of Medicine

Immunocore Presents Data At the European Society for Medical Oncology (Esmo) Congress 2021 Demonstrating A Reduction in Circulating Tumor DNA (ctDNA) While on Tebentafusp Is Associated with Overall Survival in the Phase 2 Clinical Trial

Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

An unknown buyer acquired stake in Immunocore Holdings plc (NasdaqGS:IMCR) from Medigene AG (XTRA:MDG1) for $4.7 million.

Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

Second quarter 2021 earnings released: UK£0.75 loss per share (vs UK£0.63 loss in 2Q 2020)

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad